Fluad vs. Fluzone High-Dose Vaccine Effectiveness Among Adults ≥65 Years
Eligible age
65+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
Yes
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study will evaluate the relative vaccine effectiveness of quadrivalent adjuvanted inactivated influenza vaccine (aIIV4) versus quadrivalent high-dose inactivated influenza vaccine (HD-IIV4) in preventing polymerase chain reaction (PCR)-confirmed influenza and influenza-related outcomes in adults ≥65 years of age during the 2023/24, 2024/25, and 2026/27 influenza seasons. The study is an observational study conducted at Kaiser Permanente Northern California (KPNC), an integrated health care system in the United States.
Sponsor: Kaiser Permanente
You may qualify if…
- ✓ Age ≥65 years at the time of influenza vaccination
- ✓ KPNC member at the time of vaccination
- ✓ Receive either aIIV4 or HD-IIV4 at a KPNC facility during the 2023/24 and/or 2024/25 influenza seasons
You may not qualify if…
- ✕ Age \<65 years at the time of influenza vaccination
- ✕ Received either aIIV4 or HD-IIV4 in the inpatient setting
- ✕ Receive more than one influenza vaccination during a single season period (i.e., 2023/24 or 2024/25 influenza seasons)
- ✕ Receive an influenza vaccination outside of KPNC
Where it's recruiting
Oakland
Source: ClinicalTrials.gov · NCT06029933 · last updated 2026-08-05